Cholangiocarcinoma

LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...